| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2023: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2022: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2021: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
|
|---|
| Outline of Final Research Achievements |
Malaria is one of the three major infectious diseases caused by the infection with Plasmodium species. Malaria drugs (antimalarial drugs) are an essential component of malaria control, but the emergence of drug resistance is a significant challenge. Antimalarial drugs are believed to cure malaria by directly killing Plasmodium parasites even in vivo, but our studies have demonstrated that the host immune system is involved in the pharmacological action of antimalarial drugs in vivo. In particular, our findings indicated that host immunoglobulins play a pivotal role in the malaria-curing action of chloroquine, the most widely used antimalarial drug. Furthermore, our results suggested that immunoglobulin-producing B cells themselves have a negative impact on the mode of action of chloroquine in vivo.
|
